VAXX
vs
S&P 500
VAXX
S&P 500
Over the past 12 months, VAXX has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.
Stocks Performance
VAXX vs S&P 500
Performance Gap
VAXX vs S&P 500
Performance By Year
VAXX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Vaxxinity Inc
Glance View
Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company is headquartered in Dallas, Texas and currently employs 89 full-time employees. The company went IPO on 2021-11-11. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) enables a new class of therapeutics that will improve the access to treatments for a range of indications. Its Vaxxine Platform is designed to connect the immune system to convert the body into its own drug factory, stimulating the production of antibodies with a therapeutic or protective effect. Its technology uses synthetic peptides to mimic and optimally combine biological epitopes in order to selectively activate the immune system, producing antibodies against only the desired targets, including self-antigens, making possible the safe and effective treatment of chronic diseases by vaccines. The modular and synthetic nature of its Vaxxine Platform provides significant in candidate development and has generated multiple product candidates that it is designing for many chronic diseases.
